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Background: Recent increasing trends in breast cancer incidence and survival have resulted in unprecedented numbers
of cancer survivors in the general population. A cancer diagnosis may have a profound psychological impact, and breast
cancer treatments often cause long-term physical sequelae, potentially affecting women’s mental health. The aim of this
systematic review is to identify and summarise all studies that have compared mental health outcomes in breast cancer
survivors, versus women who did not have cancer.
Methods: This study will be a systematic review of the literature. Four databases, including MEDLINE and PsycINFO, will
be searched to identify potentially relevant studies. The search expressions will use a Boolean logic, including terms for
the target population (women who have had breast cancer), outcomes (psychiatric disorders) and comparators (e.g. risk,
hazard). All mental disorders will be eligible, except those with onset normally occurring during childhood or strong
genetic basis (e.g. Huntington disease). The eligibility of the studies will be assessed in two phases: (1) considering the
information provided in the title and abstract; (2) evaluating the full text. Studies including women diagnosed with
breast cancer 1 year or more ago and that provide original data on mental health outcomes will be eligible. Studies in
which all women were undergoing surgery, chemotherapy or radiotherapy, or hospitalised or institutionalised, will be
excluded, as well as studies that include patients selected on the basis of symptomatology. Two investigators will do the
screening of the references and the data extraction independently, with results compared and discrepancies resolved by
involving a third investigator when necessary. Study quality and risk of bias will be assessed across six broad domains.
Results will be summarised by outcome, and summary measures of frequency and/or association will be computed if
possible.
Discussion: This review will summarise the evidence on the mental health outcomes of women who have been
diagnosed with breast cancer. This information can be used to motivate further research and increase understanding
of the most common mental health conditions affecting this growing population of women.
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Survival from breast cancer increased markedly during the
last decades [1]. In 2005–2009, 5-year age-standardised net
survival was higher than 85% in North America and be-
tween 71 and 87% in 29 European countries [1]. Consider-
ing that breast cancer is the most frequent malignancy
diagnosed in women worldwide, after non-melanoma skin
cancer [2], this has already translated into an unprecedent-
edly large number of breast cancer survivors in the general
population. Many women find the diagnosis a traumatic ex-
perience [3], and the usual reactions include anxiety, hope-
lessness, anger and negative and suicidal thoughts [4, 5].
Some of the treatments can also cause severe long-term
suffering. For example, surgery usually results in a lifelong
scar and may cause breast shape alteration, persistent pain
and/or lymphoedema [6–8]. The diagnosis and treatment
of the breast cancer might also affect the woman’s family,
including intimacy with their partners [9] and relationships
with their offspring [10]. Women who return to work may
also face new challenges, not only in the relationship with
their work colleagues [11] but also in their cognitive func-
tioning [12, 13]. Women must also deal with the fear of
cancer recurrence and death [14]. All of these factors may
have a long-term negative impact on the mental health of
breast cancer survivors.
Several systematic reviews summarised the frequency
of selected mental health outcomes in oncological pa-
tients under and post-treatment [15–22]. Two reviews
focused on breast cancer survivors [16, 22]. Howard-
Anderson et al. [22] focused on younger breast cancer
survivors (<50 years at diagnosis), an important group
but who represent a small proportion of all breast cancer
survivors. The systematic review by Maass et al. [16] re-
ported prevalences of anxiety between 18 and 33% and
of depression between 9 and 66%; however, most of the
studies included in this review did not involve a compari-
son group, and therefore, it is unclear how the figures
compare to those of women who did not have cancer. The
range of adverse mental health outcomes in breast cancer
survivors is also unlikely to be limited to anxiety and de-
pressive disorders alone. Other outcomes, such as sleep
disturbances, have been reported as frequent during the
treatment period and afterwards [23, 24], and very little is
known about the long-term impact of these in breast can-
cer patients.
The overall aim of this study is to identify and sum-
marise studies that have quantitatively compared mental
health outcomes in breast cancer survivors of at least
1 year since diagnosis, versus women who did not have
cancer. Specifically, through summarising such studies,
this systematic review will:
 Identify mental disorders that may be associated
with a history of breast cancer Summarise and, where possible, synthesise
quantitative estimates of associations between breast
cancer history and a range of specific psychiatric
outcomes
 Summarise the instruments used to evaluate mental
disorders or their severity in breast cancer survivors
Methods
This systematic review protocol follows the guidance
outlined by the Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) [25].
Additional file 1 provides information for each item of
the PRISMA-P checklist. This review has been registered
in the International prospective register of systematic re-
views (PROSPERO 2017:CRD42017056946).
Eligibility
Inclusion criteria
Manuscripts reporting studies satisfying the following cri-
teria will be eligible for inclusion:
– Based on original data.
– Uses any observational study design (i.e. cohort,
case-control, cross-sectional designs).
– Includes adult women (≥18 years) diagnosed with
breast cancer and who survived the first year after
the diagnosis.
– Includes a population-based adult female comparison
group with no prior cancer.
– Provides data on at least one of our pre-specified
mental health outcomes of interest, namely the
following: anxiety disorders; bipolar and related
disorders; disruptive, impulse control and conduct
disorders; feeding and eating disorders; mood
disorders; neurocognitive disorders; neurotic
disorders; personality disorders; schizophrenia
spectrum and other psychotic disorders; sexual
dysfunctions of a psychological nature; sleep-wake
disorders; somatoform disorders; substance-related
disorders (including alcoholism); and trauma- and
stressor-related disorders. Studies providing data on
self-injurious behaviour (including self-harm, suicide
and suicidal ideation) will also be included. These
outcomes were selected by reviewing the list of
mental disorders available in the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition
[26] and the ICD-10 Classification of Mental and
Behavioural Disorders [27].
Exclusions
Articles will be excluded according to the following criteria:
– Review articles, editorials, commentaries, conference
abstracts, case reports and studies involving animals.
Table 1 MEDLINE search expression, via OVID®
1 exp Breast Neoplasms/
2 (breast and (cancer* or carcinoma* or tumo?r* or neoplas*)).
mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary
concept word, unique identifier]
3 1 or 2
4 exp catatonia/ or exp depression/ or exp self-injurious behavior/
or exp anxiety/
5 mental disorders/ or exp anxiety disorders/ or exp “bipolar and
related disorders”/ or exp “disruptive, impulse control, and
conduct disorders”/ or exp dissociative disorders/ or “feeding
and eating disorders”/ or anorexia nervosa/ or binge-eating
disorder/ or bulimia nervosa/ or pica/ or exp mood disorders/
or exp motor disorders/ or neurocognitive disorders/ or amnesia/
or cognition disorders/ or auditory perceptual disorders/ or mild
cognitive impairment/ or consciousness disorders/ or delirium/
or dementia/ or exp neurotic disorders/ or exp personality
disorders/ or exp “schizophrenia spectrum and other psychotic
disorders”/ or sexual dysfunctions, psychological/ or exp sleep
wake disorders/ or exp somatoform disorders/ or exp substance-
related disorders/ or exp “trauma and stressor related disorders”/
6 (depressi* or dysthymia or catatonia or self-injur* or self-injury
or self-injurious or self-mutilation or “self mutilation” or suicid*
or self-harm or “self harm” or “self injury” or anxious* or anxiety
or (panic adj1 (disorder# or attack#)) or catastrophi* or (mental
adj1 (disorder or disorders)) or phobia or phobic or neurotic or
(compulsive adj1 disorder) or bipolar or neurotic or (personality
adj1 disorder) or psychotic or psychosis or paranoid or delusional
or (sexual adj1 (disorder or dysfunction or problem#)) or
insomnias or (sleep adj1 (disorder or dysfunction or problem#))
or somatoform or (substance adj3 (disorder or problem#)) or
stress ajd3 disorder or (adjustment adj3 disorder)).mp. [mp=title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier]
7 4 or 5 or 6
8 (prevalence# or frequenc* or incidence# or risk or rate* or ratio
or odds or epidemiolog* or percent* or outcomes or hazard).mp.
[mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique
identifier]
9 3 and 7 and 8
10 Humans/
11 Animals/
12 10 and 11
13 11 not 12
14 9 not 13
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survivors depended on symptoms (e.g. only patients
with persistent pain or fatigued) or on a mental
health outcome (e.g. only women with depression).
– Studies which only presented data for the first year
after the breast cancer diagnosis; however, studies
following women from diagnosis may still be eligible
if outcomes at ≥ 1 year or more since diagnosis are
reported separately.
– Studies in which all breast cancer patients remain
under treatment for cancer (except for long-term
endocrine therapy) at the time of outcome
ascertainment.
– Studies in which all women are institutionalised
(e.g. hospitalised or in hospices).
Search strategy
We will consider as potentially eligible all studies pub-
lished in the journals indexed in MEDLINE, PsycINFO,
the Cumulative Index to Nursing and Allied Health
Literature (CINAHL) and the Social Sciences Citation
Index, since the inception of each database up to when
the database was last updated at the time of the search.
A search expression will be defined with a Boolean logic,
including terms for the target population (breast cancer
patients), outcome (psychiatric disorder) and compara-
tors (risk, hazard, etc.). The search expression used in
MEDLINE includes terms for Medical Subject Headings
(MeSH) as well as key text words with truncation to
allow for variations in terminology (Table 1). The search
expression will be adapted to each database, to take into
account the specificities of the search algorithms.
We will restrict the search to studies including humans.
We will not apply any time, geographic or language re-
striction. If a study is published in a language not suffi-
ciently understood by the authors, we will seek assistance
to translate/understand the content.
Backwards and forward citation tracking will also be
used to identify additional potential eligible studies that
were not captured by the database searches.
Data management and selection process
All records will be imported into EndNote X7 (EndNote
X7, Thomson Reuters, NY, USA), and studies identified
as duplicates by the software will be removed. A backup
of the search expression and the records obtained from
each database, as well as the date of last update and run,
will be saved.
The references will be screened in two consecutive
phases by two authors (HC and MM, or HC and RH). In
the first phase, the title and the abstract of each study
will be read to determine their eligibility for the study by
applying the pre-defined inclusion and exclusion criteria
(see the “Eligibility” section above). If the informationprovided in the title and abstract does not allow the un-
equivocal exclusion of the study, the full text will be
considered. In the second phase, the full text of each
study considered eligible in the first phase will be ob-
tained and read in order to determine the eligibility con-
sidering all the information in the paper. The studies
will be reassessed for data extraction.
The decisions taken independently by each of the in-
vestigators will be compared, and discrepancies will be
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(RW or KB). The agreement between the two investiga-
tors will be calculated (kappa statistics).
If more than one study reports data on the same study
population, we will include only the study providing data
for the largest sample; if the sample size is the same, we
will consider the study providing more detailed informa-
tion on outcomes (e.g. results stratified for age or type
of treatment received) and consider both studies for ab-
straction of information on the participants’ characteris-
tics (e.g. age, menopausal status, stage at diagnosis).
A record of excluded/included studies, with the re-
spective exclusion criterion, will be kept, and the selec-
tion process including numbers excluded at each stage
for different criteria will be summarised in a flow chart.
Data extraction
Two authors (HC and MM, or HC and RH) will extract
data from each included study into a pre-defined form
in Microsoft Office Excel (2013). The form will be
piloted using four studies and adapted if necessary. In-
formation will be collected on (1) study characteristics
(e.g. authors, year of publication, country where the
sample was obtained or duration of follow-up if applic-
able); (2) characteristics of the breast cancer survivors
(details on participant recruitment, sample size, demo-
graphics, distribution of stage at diagnosis, time since
diagnosis and type of treatments); (3) characteristics of
the women who did not have cancer (recruitment of the
participants, sample size, demographics); (4) information
on the mental health outcomes (name of the mental
condition, diagnostic criteria, instruments applied); and
(5) quantitative information on the mental health out-
come (e.g. prevalence or mean/median score in each
group and/or relative risk comparing groups) and vari-
ables considered as potential confounders.
If a prospective study provides data for more than one
point in time, we will abstract all available information.
The data extracted by each author will be compared
and discrepancies resolved by consensus or involving a
third researcher (KB or RW) if necessary.
Risk of bias in individual studies
We will evaluate study quality and risk of bias in the ori-
ginal studies by assessing the main domains identified by
Sanderson et al. as important for observational study
quality and bias assessment [28], informed by the
“STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE)” guidelines [29]. These do-
mains are: methods for selecting study participants,
methods for measuring the exposure and the outcome
variables, design-specific sources of bias (excluding con-
founding), methods to control for confounding, statis-
tical methods (excluding confounding) and conflict ofinterest [28]. Within each of the above domains, individual
studies will be rated as at high risk of bias, low risk of bias
or unclear risk of bias, following the Cochrane Collabor-
ation approach formulated for clinical trials [30].
Data analysis and synthesis
The results will be reported according to the PRISMA
guidelines [31]. Tables and descriptive text will be used
to summarise study characteristics and results, stratified
by outcome and likely sources of heterogeneity (e.g.
study design, type of population).
Quantitative synthesis of results (meta-analysis) will
only be attempted for selected outcomes where deemed
appropriate, taking into account the number of studies
available, study designs and methods and equivalence of
outcome measures and effect estimates used. Where
quantitative synthesis is attempted, the DerSimonian
and Laird method [32] will be used to compute sum-
mary estimates of the association between breast cancer
and the discrete psychiatric outcome in question, along
with 95% confidence intervals. Sub-group analyses by
time since diagnosis will be conducted if possible. Pro-
spective studies providing data for two or more time
points after the first anniversary of diagnosis will be in-
cluded once in meta-analysis; the relative risk estimate
for the first eligible time point will be chosen. Hetero-
geneity will be quantified using Higgins and Thompson’s
I-squared statistic [33]. The meta-analysis will be re-
peated excluding any studies identified as at high risk of
bias in the quality assessment. For outcomes deemed
suitable for meta-analysis as described above, funnel
plots and Egger’s regression asymmetry test [34] will be
used to assess publication bias and small study effects if
more than ten studies are available [35].
Discussion
The number of women who have had breast cancer is
higher than ever before. These women may face many
challenges when trying to assimilate back into life fol-
lowing their cancer diagnosis and treatment, and it is
imperative to understand the long-term psychological
consequences. This systematic review aims to provide a
comprehensive overview of the associations between
breast cancer history and mental health conditions.
Most reviews on the topic have been restricted to study-
ing the prevalence of depression among cancer patients
[15, 20]. We opted for considering a much broader list of
mental disorders that have their onset during adulthood
as outcomes, to give a more comprehensive picture of the
spectrum of mental disorders that may affect breast can-
cer survivors. We also chose to include only studies in
which a comparison group was available, so that the rela-
tive frequency or severity of these conditions compared to
the general population could be studied.
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nosed with breast cancer at least one year prior to out-
come measurement. Women who completed breast
cancer treatments with curative intent (i.e. surgery,
chemotherapy and/or radiotherapy) are often considered
as survivors; however, the precise point in time when
the treatments end is frequently unknown and a widely
accepted definition of cancer survivor does not exist
[36]. Researchers commonly use a fixed point in time to
capture, in a pragmatic way, the moment at which the
main course of treatment is likely to have been com-
pleted. At 1 year after the diagnosis, the vast majority of
women are expected to have completed the main treat-
ments and many have returned to their pre-cancer rou-
tines. The effect of having been diagnosed and treated for
breast cancer may also vary over time [37], and thus, an
adequate characterisation of the risk of mental disorders
requires a known time since diagnosis.
Studies involving mental health outcomes are prone to
selection bias. We will report the characteristics of the
samples involved in the original studies, including the
details on the recruitment of the participants. We will
also evaluate and report the risk of bias and use this in-
formation to help interpret the results.
Mental disorders largely interfere with the functioning
of the patients and are leading causes of disability world-
wide [38]. The mean prevalence of depression among
women who had breast cancer has been described in the
range between 10 and 20%, depending on the methods
used to evaluate it [15]. This indicates that the burden of
at least depressive disorders in this population is far
from negligible. The impairments caused by depression
are likely to be higher in these women than in women
with depression alone [39].
Even though there are several pharmacological and
non-pharmacological treatments available, mental disor-
ders are often undiagnosed and untreated. The results of
this review can be used to inform health professionals
about the range, frequency and severity of mental disor-
ders among breast cancer survivors.
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